MBC Applying New Developments

CE / CME

Applying the Latest Developments in Metastatic Breast Cancer Through Education of Healthcare Professionals, Patients, and Caregivers

Nurses: 1.50 Nursing contact hours

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: October 19, 2023

Expiration: October 18, 2024

Joyce O'Shaughnessy
Joyce O'Shaughnessy, MD

Activity

Progress
1
Course Completed

Trastuzumab + Docetaxel ± Pertuzumab in Untreated HER2-Positive Metastatic Breast Cancer (CLEOPATRA): PFS

I would like to move on to talk about HER2-positive MBC and the available treatment options in the first-line setting. The phase III CLEOPATRA trial established first-line trastuzumab plus pertuzumab and docetaxel as a standard of care for patients with HER2-positive MBC.17 Final data from the CLEOPATRA trial, shown on the right, documented a substantial improvement in OS with the addition of pertuzumab to trastuzumab and docetaxel.18 The absolute improvement in OS was 16.3 months (median OS: 57.1 vs 40.8 months; P <.0001). Moreover, based on the landmark analysis at 8 years, 37% of patients who received the pertuzumab-containing regimen remained alive compared with 23% who received the regimen without pertuzumab. Based on these data, pertuzumab, trastuzumab, and docetaxel remain the standard of care in the first-line setting for patients with HER2-positive MBC.